SS-31 Evidence Guide
Evidence for SS-31 (elamipretide) is too preliminary to support a research protocol with confidence. Despite promising mitochondrial mechanistic data and early trials, Phase 3 results for Barth syndrome and heart failure have been mixed or failed to meet primary endpoints. Of the Anti-Aging & Longevity compounds, NAD+ precursors and carnosine have better-established human evidence profiles.
Our Take
Evidence for SS-31 (elamipretide) is too preliminary to support a research protocol with confidence. Despite promising mitochondrial mechanistic data and early trials, Phase 3 results for Barth syndrome and heart failure have been mixed or failed to meet primary endpoints. Of the Anti-Aging & Longevity compounds, NAD+ precursors and carnosine have better-established human evidence profiles.
- Best for
- Mitochondrial dysfunction research, cardioprotection, oxidative stress
- Evidence grade
- Level B
- Confidence
- Low
- Starting point
- No validated outpatient human protocol - clinical trials use 40mg/day IV
Benefits and Evidence
- Mitochondrial Function: Level B, includes human evidence - Consistent improvement in mitochondrial function across preclinical and clinical studies. Restores impaired mitochondrial energetics in aging and disease models.
- Heart Failure: Level B, includes human evidence - Phase 2/3 trials in heart failure show improvements in cardiac function and exercise capacity. PROGRESS-HF trial showed mixed results on primary endpoint but positive secondary outcomes.
- Exercise Capacity: Level B, includes human evidence - Clinical trials demonstrate improved exercise tolerance in heart failure and mitochondrial myopathy patients. Related to enhanced mitochondrial ATP production.
- Kidney Protection: Level C, includes human evidence - Preliminary evidence of renoprotective effects, particularly in ischemia-reperfusion injury. Clinical trials ongoing for acute kidney injury prevention.
Side Effects and Warnings
- Injection site reactions
- Headache
- Mild gastrointestinal symptoms
- Generally well-tolerated in clinical trials
- Still in clinical trials, not yet FDA-approved
- Long-term safety profile not fully established
- Some clinical trials have shown mixed results
- Cost may be significant if approved
Research Dosage References
- <strong>Subcutaneous injection</strong> - 40 mg - Once daily - Clinical trial dosing for heart failure. Lower doses (4-40mg) studied in various conditions.
- <strong>Intravenous</strong> - 0.05 mg/kg/hr - Continuous infusion - Used in acute settings (cardiac surgery, reperfusion injury). Duration varies by protocol.
Mechanism of Action
SS-31 targets mitochondrial function: 1. Cardiolipin binding: Selectively binds to cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure. 2. Electron transport optimization: Improves electron flow through the respiratory chain, reducing electron leak and ROS production. 3. ATP production enhancement: Increases mitochondrial ATP output by optimizing oxidative phosphorylation. 4. ROS reduction: Decreases mitochondrial reactive oxygen species at their source rather than scavenging after production. 5. Mitochondrial dynamics: Promotes healthy mitochondrial fusion/fission balance and prevents pathological fragmentation.
Legal Status
Investigational drug in Phase 3 clinical trials. Not yet FDA-approved. Fast Track designation from FDA for Barth syndrome. Orphan drug designation for several rare mitochondrial conditions. Not available as a research peptide in most markets.
Primary Sources
- A Phase 2 Trial of Elamipretide in Heart Failure (PROGRESS-HF). JACC Heart Fail, 2020.
- Elamipretide in Barth syndrome: a randomized, double-blind trial (TAZPOWER). Heart, 2021.
- Mitochondria-targeted peptides for cardioprotection. Pharmacol Ther, 2014.